Welcome to our dedicated page for Sanofi news (Ticker: SNY), a resource for investors and traders seeking the latest updates and insights on Sanofi stock.
Sanofi reports news as a global biopharmaceutical issuer with American depositary shares traded under SNY. Company updates center on medicines and vaccines built around immunology, specialty care, rare diseases, diabetes, respiratory disease and infectious-disease prevention, including recurring developments for products such as Dupixent, BEYFORTUS, insulins and pipeline candidates.
Sanofi news also covers clinical and regulatory milestones, collaborations with biotechnology and diagnostics partners, patient-access programs, community health initiatives, leadership changes and capital-allocation actions. As a foreign issuer, updates may reflect both parent-company announcements and ADR-related public-company disclosures.
Sanofi (SNY) and USA Pickleball have launched the “Serve Up Protection” campaign on September 10, 2026 to educate older adults about COVID-19 and NUVAXOVID, the only protein-based, non-mRNA COVID-19 vaccine approved by the FDA.
The initiative targets adults 65+ during respiratory season, using multimedia education, trusted pickleball voices and fan experiences at major events, including USA Pickleball’s National Championships in November in San Diego. The campaign addresses that nearly 70% of adults 65 and older remain unvaccinated, partly due to concerns about side effects.
NUVAXOVID is indicated for people 65+ and for those 12–64 at high risk for severe COVID-19. In two pivotal phase 3 trials it showed high efficacy, with most side effects mild to moderate, though rare serious reactions, including severe allergy, myocarditis and pericarditis, are possible. Sanofi is market authorization holder in the US, EU and UK and is expanding NUVAXOVID’s availability to additional countries from 2026.
Sanofi (SNY) is partnering with Emmy Award-winning actress and mother Keke Palmer to educate parents about protecting babies from serious respiratory syncytial virus (RSV) lung infection using BEYFORTUS (nirsevimab-alip). Palmer’s own baby received BEYFORTUS after discussion with his pediatrician, and the campaign urges families to talk with their baby’s doctor about RSV protection during RSV season, which typically runs from fall through spring in most of the United States.
BEYFORTUS is a single-dose, long-acting monoclonal antibody approved to help prevent serious RSV lower respiratory tract disease in newborns and infants entering their first RSV season, and in children up to 24 months of age who remain at risk through their second season. The medicine is described as the #1 prescribed RSV immunization for babies in the US, and more than 11 million parents in the US have chosen it for their babies.
Sanofi (NYSE:SNY) is an inaugural industry sponsor of AlphaDetect, supporting expansion of routine detection for Alpha-1 Antitrypsin Deficiency. The sponsorship aims to increase provider education, broaden detection strategies and scale proven testing tools so clinical guideline recommendations for testing patients with COPD, treatment-resistant asthma, or unexplained liver disease are more widely followed.
Sanofi (NYSE:SNY) announced a leadership change in its Specialty Care Global Business Unit: Manuela Buxo will become Head of Specialty Care effective March 1, 2026, succeeding Brian Foard, who will leave the company on February 28, 2026 to pursue an external leadership opportunity.
Manuela currently leads the Global Immunology Alliance Franchise from Cambridge, Mass., has over 20 years of international healthcare experience, and for more than two years has driven global expansion of Dupixent. Sanofi says this change aims to ensure continuity and maintain momentum in Specialty Care.
Dren Bio expanded a strategic collaboration with Sanofi (SNY) to discover next-generation B-cell depletion multispecific antibody therapeutics using Dren Bio’s Targeted Myeloid Engager and Phagocytosis platform.
Deal terms include a $100 million upfront payment and up to $1.7 billion in development, regulatory, and commercial milestones. Sanofi previously acquired Dren Bio’s DR-0201 (now SAR448501), which is in two ongoing Phase 1 studies showing robust B-cell depletion. Dren Bio may co-fund 40% of ongoing global development to obtain U.S. co-promotion and a 50/50 share of U.S. profits and losses, while remaining eligible for milestones and tiered royalties on ex-U.S. sales.
EVOQ Therapeutics announced a Collaboration and License Agreement with Sanofi (NASDAQ: SNY) on October 16, 2025 to advance EVOQ's NanoDisc technology for autoimmune diseases. Under the deal, Sanofi will lead development and worldwide commercialization while EVOQ is eligible to receive over $500 million in upfront, preclinical, development and sales milestones plus tiered royalties on product sales. The NanoDisc platform aims to restore immune tolerance across indications including celiac disease, type 1 diabetes, MOG antibody disease, rheumatoid arthritis and lupus.
The agreement pairs EVOQ's proprietary platform with Sanofi's immunology and commercial capabilities, transferring development and market responsibilities to Sanofi and establishing milestone-driven payments and royalty economics for EVOQ.
Revvity (NYSE:RVTY) has announced a significant program to expand its type 1 diabetes (T1D) testing capabilities, partnering with Sanofi. The initiative includes developing a T1D 4-plex in vitro diagnostic (IVD) assay based on their existing 3-plex research-use assay.
The program aims to enable population-scale screening for early-stage T1D using Revvity's GSP® instrument with both capillary dried blood spot and venous specimens. The company plans regulatory submissions to the U.S. FDA, IVDR, and other major jurisdictions. Additionally, Revvity will expand its laboratory network globally to increase access to its existing research-use product, currently offered as an LDT at their CLIA and CAP accredited Revvity Omics laboratory in Pittsburgh.
This initiative addresses a significant medical need, as over 9 million people worldwide live with T1D, with more than 500,000 new cases diagnosed annually, 90% without family history.
Sanofi (NASDAQ:SNY) has announced a significant expansion of its Insulins Valyou Savings Program, offering all Americans access to any Sanofi insulin for $35 per month, regardless of their insurance status. The expanded program, effective January 1, 2026, will be available to patients with commercial insurance, Medicare, or no insurance.
The initiative will cover all Sanofi insulins at most pharmacies across the US, including independent and rural locations. Patients can obtain any combination, type, and quantity of Sanofi insulins with a valid prescription at this fixed monthly price. The program aims to eliminate financial barriers that may lead to medication rationing or dose skipping.
Sanofi (NYSE:SNY) has partnered with celebrity mothers including Mandy Moore and other influential personalities to promote BEYFORTUS®, their RSV prevention treatment for infants. BEYFORTUS is the first long-acting monoclonal antibody approved to prevent serious RSV lung infections in babies up to 24 months old.
The campaign highlights that BEYFORTUS is designed for all babies, regardless of their health status or birth timing. The treatment has demonstrated its safety and effectiveness through clinical studies and over 50 real-world studies involving more than 400,000 babies. RSV is currently the leading cause of hospitalization in infants under one year old.
The initiative features personal stories from celebrity mothers who chose BEYFORTUS for their children, emphasizing its position as the #1 doctor-prescribed choice for RSV protection in infants.
Sanofi (NYSE:SNY) collaborated with the National Association of CHWs (NACHW), NationSwell, and Atlas Clarity to publish a new report titled "Strengthening Public Health with Community Health Workers" during National CHW Awareness Week.
The report highlights the critical role of Community Health Workers (CHWs) in bridging gaps between health services and communities, particularly in rural and underserved areas where over 76 million Americans live in Health Professional Shortage Areas. The study emphasizes successful programs where CHWs are engaged early in program design, properly compensated, and integrated effectively into care teams.
Key recommendations include partnering with CHW Networks on policy priorities, creating permanent roles for CHWs, and investing in quantifying their impact on specific diseases and ROI. The full report is available at www.nachw.org/projects/strengthening-ph-chws/.